medigraphic.com
ISSN 1561-3119 (Electronic)

2015, Number 3

<< Back Next >>

Rev Cubana Pediatr 2015; 87 (3)

IgA nephropathy, the most common glomerulopathy worldwide

Durán ÁS, Campo SL

Language: Spanish
References: 45
Page: 350-361
PDF size: 119.12 Kb.


ABSTRACT

IgA nephropathy is immunocomplex-mediated glomerulonephritis that is characterized by the A1 immunoglobulin deposition in the glomerular mesangium. It is the most frequent form of primary glomerulonephritis worldwide. The probabilities of long-term renal function deterioration increased due to the following findings: blood hypertension, persistent microscopic hematuria, proteinuria greater than 0.5 g/day, decrease of renal function when manifestations or findings of glomerular sclerosis are observed in the renal biopsy; vascular sclerosis, interstitial fibrosis, tubular atrophy, formation or distribution of IgA in the glomerular capillary walls in the immunofluorescence test. Among the clinical manifestations of IgA nephropathy is macroscopic hematuria in roughly half of patients in the first or second day after onset of the respiratory infection symptoms and is associated to flank pain in patients less than 40 years. In the oldest people, macroscopic hematuria is generally asymptomatic and occasionally detected in screening urinalysis. Ten to twenty percent of patients with mild proteinuria and hematuria may reach spontaneous remission, but 25 to 30 % of them may also progress into the terminal chronic renal disease at a general slow rate (5 to 20 years). Renal biopsy is the only specific test to confirm diagnosis. Those patients with hematuria and proteinuria of less than 0.3 g/day, whose blood pressure is normal, do not require specific drug treatment but they need to be systematically controlled through urinalysis, serum creatinine and blood hypertension taking. The patients suffering from proteinuria and hypertension must be strictly treated with converting enzyme inhibitors. Hypertension, significant proteinuria (0.5 g/day), rapidly progressive glomerulonephritis (rare) and nephrotic syndrome must be immediately managed. Tonsillectomy, frequent method in Japan, could be beneficial for those patients presenting with macroscopic hematuria and tonsillitis. Several sources were consulted to make this review.


REFERENCES

  1. Berger J, Hinglais N. IgA glomerular dépóts intercapillaires d´IgA-IgG. J Urol Nephrol. 1968;74:694-5.

  2. Berger J. IgA glomerular deposits in renal disease. Transplant Proc. 1969;1:939-44.

  3. Tomoma M, Matousovic K, Jullian BA. Galactose deficient IgA1 in sera of IgA nephropathy patients is present in complexes with IgG. Kidney Int. 1997;52:509-16.

  4. Coppo R, Amore A. Aberrant glycosylation in IgA nephropathy. Kidney Int. 2004;65:1544-7.

  5. Florín Yrabién J, Durán Álvarez S, Durán Casal DP, Cazorla Artiles N, Valdés Mesa M, Guillén Dosal A, et al. Nefropatía por depósitos de IgA. En: de la Torre Montejo E, Pelayo González-Posada EJ. Pediatría. La Habana: Editorial Ciencias Médicas; 2010. p. 2128-32.

  6. Mohey H, Laurent B, Mariat C, Berthou C. Validation of the absolute renal risk of dialysis/death in adults with IgA nephropathy secondary to Henoch-Schönlein purpura: a monocenter cohort study. BMC Nephrol. 2013;14:169.

  7. Lee H, Hwang JH, Paik JH, Ryu HJ, Kim DK, Chin HJ, et al. Long-term prognosis of clinically early IgA nephropathy is not always favorable. BMC Nephrol. 2014;15:94.

  8. Donadio JV, Grande JP. IgA nephropathy. N Engl J Med. 2002;347:738-48.

  9. Lee H, Kim DK, Oh KH, Joo KW, Kim VS, Chae DW, et al. Mortality of IgA nephropathy patients: A single center experience over 30 years. PLoS One. 2012;7:e51225.

  10. Zhu L, Shi S, Liu L, Ly J, Zhang H. Increased plasma sVCAM-1 is associated with severity in IgA nephropathy. BMC Nephrol. 2013;14:21.

  11. Kiryluk K, Novak J. The genetics and immunology of IgA nephropathy. J Clin Invest. 2014;124:2325-32.

  12. Gharavi GA, Yan Y, Scolari F, Schena FP, Frasca GM, Ghiggeri GM, et al. IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22-23. Nat Genet. 2000;26:354-7.

  13. Barratt J, Feehally J. Treatment of IgA nephropathy. Kidney Int. 2006;69:1934-8.

  14. Varma PP, Sengupta P, Nair PK. Post exertional hematuria. Renal Fail. 2014;36:701-3.

  15. Jennette JC. The immunohistology of IgA nephropathy. Am J Kidney Dis. 1988;12:348-52.

  16. Galla JH. IgA nephropathy. Kidney Int. 1995;47:377-87.

  17. Lee SMK, Rao VM, Franklin W. IgA nephropathy: morphologic predictors of progressive renal disease. Hum Pathol. 1982;13:314-22.

  18. Hass M. Histologic subclassification of IgA nephropathy: a clinic pathologic study of 244 cases. Am J Kidney Dis. 1997;29:42.

  19. Jennette JC. Immunoglobulin A nephropathy and Henoch-Schönlein purpura. In: Fogo AB, Cohen AH, Jennette JC, Brujin JA, Colvin RB. Fundamentals of renal pathology. New York: Springer Science + Business Media; 2006. p. 61-9.

  20. D’Amico G. Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Sem Nephrol. 2004;23:179-96.

  21. Le W, Lian S, Hu Y, Deng K, Bao H, Zeng C, et al. Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population. Nephrol Dial Transplant. 2012;27:1479-85.

  22. Ferri FF. IgA nephropathy. En: Ferri’s clinical advisor. New York: Mosby. 2015;644-5.

  23. Lee HJ, Choy SY, Jeong KH, Sung JY, Moon SK, Moon SJ, et al. Association of C1q deposition with renal outcome in IgA nephropathy. Clin Nephrol. 2013;80:98-104.

  24. Nam KH, Kie JH, Lee MJ, Chang TI, Kang EW, Kim DW, et al. Optimal proteinuria target for renoprotection in patients with IgA nephropathy. PLoS One. 2014 jul 8;9(7)137.

  25. Gutierrez E, Zamora I, Ballarin JA, Arce Y, Jiménez S, Quereda C, et al. Longterm outcome of IgA nephropathy presenting with minimal or no proteinuria. J Am Soc Nephrol. 2012;23:1753-60.

  26. Yamamoto R, Nagasawa Y, Shoji T, Iwatani H, Hamano T, Kawada N, et al. Cigarette smoking and progression of IgA nephropathy. Am J Kidney Dis. 2010;56:313-24.

  27. Fang J, Li W, Li D, Tan Z. Baseline proteinuria, urinary osmotic pressure, and renal function as positive predictors of corticosteroid plus cyclophosphamide treatment efficacy in IgA nephropathy. Chin Med J (Engl), 2014;127:1710-4.

  28. Liu X, Dewei D, Sun S, Xu G, Liu H, He L, et al. Treatment of severe IgA nephropathy; mycophelonate mofetil/prednisone compared to cyclophosphamide/prednisone. Int J Clin Pharmacol Ther. 2014;52:95-102.

  29. Xu L, Liu ZC, Guan GI, Ly XA, Luo Q. Cyclosporine A combined with medium/low dose prednisone in progressive IgA nephropathy. Kaohsiung J Med Sci. 2014;30:390-5.

  30. Working Group for National Survey on Status of Diagnosis and Treatment of Childhood Renal Diseases. Multicenter investigation of therapeutic status of children with IgA nephropathy in China 2013. Zhonghua Er Ke Za Zhi. 2013;51:486-90.

  31. Kawamura T, Yoshimura M, Miyazaki Y, Okamoto H, Kimura K, Hirano K; the Special IgA Nephropathy Study Group. Multicenter randomized controlled trial of tonsillectomy combined with pulse therapy in patients with immunoglobulin A nephropathy. Nephrol Dial Transplant. 2014;29:1546-53.

  32. Koyama A, Igarashi M, Kobayashi M. Natural history and risk factors for immunoglobulin A nephropathy in Japan, Research Group in Progressive Renal Diseases. Am J Kidney Dis. 1997;29:526-37.

  33. Jullian B, Barker C. Alternate-day prednisone therapy in IgA nephropathy: Preliminary analysis of a prospective, randomized, controlled trial. Contrib Nephrol. 1993;104:198-206.

  34. Pozzi C, Bolasce PG, Fogazzi GB. Corticosteroid in IgA nephropathy: A randomized, controlled trial. Lancet. 1999;353:883-7.

  35. Pozzi C, Andrulli S, Del Vecchio L. Corticosteroid effectiveness in IgA nephropathy, long-term results of a randomized, controlled trial. J Am Soc Nephrol. 2004;15:157-63.

  36. Rasche FM, Schwarz A, Keller F. Tonsillectomy does not prevent a progressive course in IgA nephropathy. Clin Nephrol. 1999;51:147-52.

  37. Hotta O, Miyazaki M, Furuta T. Tonsillectomy and steroid pulse significantly impact on clinical remission in patients with IgA nephropathy. Kidney Int. 2001;63:1861-7.

  38. Ohya M, Otani H, Minami Y, Yamanaka S, Mima T, Negi S, et al. Tonsillectomy with steroid pulse therapy has more effect on the relapse rate than steroid pulse monotherapy in IgA nephropathy patients. Clin Nephrol. 2013;80:47-52.

  39. Moriyama T, Tanaka K, Iwasaki C, Oshima Y, Ochi A, Kataoka H, et al. Prognosis in IgA nephropathy: 30-year analysis of 1 012 patients in a single center in Japan. PLoS One. 2014;9:e91756.

  40. Vergano L, Loiacono E, Albera R, Coppo R, Camilla R, Peruzzi L, et al. Can tonsillectomy modify the innate and adaptive immunity pathways in IgA nephropathy? J Nephrol. 2014;PMID:24756968.

  41. Wang Y, Ichimaru N, Kyo M, Kakuta Y, Okumi M, Kaimon JY, et al. Beneficial effects of tonsillectomy for mesangial immunoglobulin A (IgA) deposition and clinical outcome in five kidney transplant patients with recurrent IgA nephropathy: Case report. Transplant Proc. 2014;46:607-9.

  42. Miura N, Imai H, Kikuchi S, Hayashi S, Endoh M, Kawamura T, et al. Tonsillectomy and steroid pulse (TSP) therapy for patients with IgA nephropathy: A nationwide survey of TSP therapy in Japan and an analysis of the predictive factors for resistance to TSP therapy. Clin Exp Nephrol. 2009;13:460-6.

  43. Tabata T, Ohbuchi T, Kitamura T, Ohkubo J, Hashida K, Hohchi N, et al. Prognostic factors of IgA nephropathy. Nihon Jibiinkoka Gakkai Raiho. 2012;115:836-41.

  44. Matsuzaki K, Suzuki Y, Nakata J, Sakamoto N, Horikoshi S, Kawamura T, et al. Nationwide survey on current treatments for IgA nephropathy in Japan. Clin Exp Nephrol. 2013;17:827-33.

  45. Hartono C, Muthukumar T. Treating IgA nephropathy: Quid Novi? Discov Med. 2014;17:131-8.




2020     |     www.medigraphic.com